ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 20 Issue : 4
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Major adverse cardiac events and drug-coated balloon size in coronary interventions [Anatol J Cardiol]
Anatol J Cardiol. 2018; 19(6): 382-387 | DOI: 10.14744/AnatolJCardiol.2018.67864  

Major adverse cardiac events and drug-coated balloon size in coronary interventions

David Naguib, Betül Knoop, Lisa Dannenberg, Eva Liebsch, Martin Pöhl, Carolin Helten, Athena Assadi-schmidt, Malte Kelm, Tobias Zeus, Amin Polzin
Division of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Düsseldorf; Düsseldorf-Germany

Objective: In-stent restenosis (ISR) is a feared complication after coronary stent implantation. Drug-coated balloon (DCB) is being promoted as a treatment option for ISR. However, the benefit-risk ratio of DCB length has not been investigated. Longer DCBs release more anti-proliferative drug to the vessel wall; however, they are associated with a higher lesion length and vessel injury. Hypothesis: DCB length is associated with clinical outcome.
Methods: We analyzed 286 consecutive Pantera Lux (Biotronik, active component Paclitaxel) DCB-treated patients between April 2009 and June 2012. Of them, 176 patients were treated using a 15-mm DCB and 109 were treated using a 20-mm DCB. Baseline characteristics and major adverse cardiac events (MACE; death, myocardial infarction, and target lesion revascularization) during initial hospital stay and a 2-year follow-up period were obtained.
Results: Patients characteristics such as cardiovascular risk factors, prior diseases, co-medication, clinical presentation, target vessel, and left ventricular function did not differ between the groups. MACE during hospital course was similar [1.7% vs. 2.8%, relative risk (RR) 1.6, 95% confidence interval (CI) 0.3-7.9, p=0.554]. Likewise, at 2-year follow-up, MACE did not differ between the groups (23.2% vs. 27.5%, RR 1.2, 95% CI 0.6-1.5, p=0.408).
Conclusion: DCB length was not associated with clinical outcome during a 2-year follow-up period.

Keywords: drug-coated balloon, drug-eluting stent, MACE, paclitaxel


David Naguib, Betül Knoop, Lisa Dannenberg, Eva Liebsch, Martin Pöhl, Carolin Helten, Athena Assadi-schmidt, Malte Kelm, Tobias Zeus, Amin Polzin. Major adverse cardiac events and drug-coated balloon size in coronary interventions. Anatol J Cardiol. 2018; 19(6): 382-387

Corresponding Author: Lisa Dannenberg, Germany


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2018 Turkish Society of Cardiology